SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-18-074266
Filing Date
2018-12-21
Accepted
2018-12-21 07:42:34
Documents
3
Period of Report
2018-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a18-41991_18k.htm 8-K 37263
2 EX-99.1 a18-41991_1ex99d1.htm EX-99.1 14400
3 GRAPHIC g419911mmi001.jpg GRAPHIC 4017
  Complete submission text file 0001104659-18-074266.txt   58771
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 181247571
SIC: 2834 Pharmaceutical Preparations